Understanding how PD-1 affects B cells in breast cancer
Function of PD-1 Signaling on the Activity of B cells in the Tumor Microenvironment in Breast Cancer
This study is looking at how a specific protein called PD-1 affects B cells in breast cancer, especially the harder-to-treat triple negative type, to find ways to make immune therapies work better for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10995813 on NIH RePORTER |
What this research studies
This research investigates the role of PD-1 signaling in B cells within the tumor microenvironment of breast cancer, particularly focusing on triple negative breast cancer. The study aims to explore how PD-1 influences B cell behavior and metabolism, which may impact the effectiveness of immune checkpoint inhibitor therapies. By examining the interactions between B cells and other immune cells, the research seeks to uncover mechanisms that could enhance treatment outcomes for patients. The findings could lead to improved strategies for utilizing PD-1-targeted therapies in breast cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who are considering or undergoing immune checkpoint inhibitor therapy.
Not a fit: Patients with non-breast cancer types or those not eligible for immune checkpoint inhibitor therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with triple negative breast cancer by improving the efficacy of immune therapies.
How similar studies have performed: Previous research has shown promising results in understanding immune checkpoint inhibitors, but the specific focus on PD-1 signaling in B cells within breast cancer is relatively novel.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Pan, Xiaolu — Univ of North Carolina Chapel Hill
- Study coordinator: Pan, Xiaolu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.